Medicinal cannabis use has increased rapidly in Australia over recent years. But there’s limited evidence it helps the conditions it’s most commonly prescribed for.
Articles on Cannabinoids
Displaying 1 - 20 of 27 articles
Any reduction in sleep time for people with clinical insomnia could be concerning.
Thirty-eight per cent of Danish dog owners surveyed said they dosed canines with cannabis products.
One in seven Canadian veterans is living with PTSD. Developing a psychedelics research program for veterans should be a public health priority.
A THC-like substance that occurs naturally in humans and other vertebrates helps maintain immunity, memory, nerve function and more – and research suggests a lack of it can harm health.
Studies suggest that marijuana and CBD use might help relieve chronic pain while also reducing a patient’s need for opioids.
With the dual threats of antibiotic resistance and emerging pandemics, finding new drugs becomes even more urgent. A trove of medicines may be lying under our nose.
Different painkillers provide relief in different ways. The most effective medication is the one that best targets the type of pain you’re experiencing with minimal side effects.
A growing body of research points to the body’s natural cannabinoid system as the primary driver behind the runner’s high – and the mental health boost and stress relief following exercise.
Cannabis labelling is often misleading. Labelling cannabis products with quantities of key compounds will help consumers make informed decisions.
Weed, though far less dangerous than many other drugs, is not entirely without risk. Some 59% of people treating pain with medical cannabis experience moderate to severe withdrawal symptoms
The jury’s still out on whether or not CBD relieves stress and anxiety.
Cannabis use is common among trauma survivors, and may improve some of the symptoms of those with PTSD.
There is no doubt a regulated market for access to medicinal cannabis is safer, but if cannabis-based products were allowed to bypass efficacy trials, there’s a potential cost to patient safety.
Radula liverwort shares an intriguing similarity to cannabis – researchers are working out what it does to the brain.
We’ve got better at managing the health risks of traditional drugs of abuse, but novel psychoactive substances, or ‘legal highs’, are a dangerous unknown.
As Canada moves towards legalization of cannabis in 2018, there is growing evidence of the drug’s potential to treat opioid addiction itself, as well as the chronic pain that often drives it.
Mexico and Canada are about to turn medical cannabis into North America’s most lucrative new market.
NSW is about to embark on the largest and most definitive clinical trial ever of medicinal cannabis for chemotherapy-induced nausea and vomiting.
The Australian government will now accept licence applications for groups wanting to grow cannabis for scientific and medical purposes. But there’s still a lot we don’t know about this complex plant.
Top contributors
-
Assistant Professor of Psychiatry and Behavioral Neurosciences, Wayne State University
-
Research Scientist, BC Centre on Substance Use and Assistant Professor in the Division of AIDS, Department of Medicine, University of British Columbia
-
Professor of Psychopharmacology and NHMRC Principal Research Fellow, University of Sydney
-
PhD student in Population and Public Health, University of British Columbia
-
Professor of Criminology and Social Policy, Manchester Metropolitan University
-
Professor of Neuropharmacology, University of Lancashire
-
Associate Professor in Psychopharmacology and Addiction Medicine at the School of Psychology, University of Sydney
-
Senior Lecturer in Biomedical and Life Sciences, Lancaster University
-
Postdoctoral Research Associate in Cancer Research, Newcastle University
-
Medical oncologist from Chris O`Brien Lifehouse cancer hospital, Lead researcher NSW Government clinical trial into the role of cannabis-derived medicines in chemotherapy-induced nausea and vomiting, Clinical Associate Professor., University of Sydney
-
Senior Research Fellow, St George's, University of London
-
Reader & Director of MANDRAKE, Manchester Metropolitan University
-
Research Associate, University of Connecticut
-
Professor in Criminology, Loughborough University
-
Medicinal Chemist, UNSW